If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
2.20    0.55 (33.33%)
Bid:
1.40
Ask:
1.99
Spread: 0.59 (42.143%)
Market Cap: £7.72m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Directorate Change

1 Jul 2014 07:00

RNS Number : 9952K
Proteome Sciences PLC
01 July 2014
 



 

 

 

 

 

PRESS RELEASE

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Roger McDowell as Non-Executive Director

 

1st July, 2014 Proteome Sciences is pleased to announce the appointment of Roger Steven McDowell to the Board of the Company as a non-executive Director with immediate effect.

 

Roger McDowell has a highly successful career as a businessman and entrepreneur. He was Managing Director of Oliver Ashworth for eighteen years before its sale to St. Gobain. He is currently the Chairman or a non-executive director of seven listed companies, namely Avingtrans plc, Servelec Group plc, Renovo plc, Alkane Energy plc, Swallowfield plc, IS Solutions plc and Augean plc. He brings considerable commercial experience with him and is a keen exponent of growing shareholder value.

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Roger Steven McDowell, age 60 years, is or has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships Past directorships

Corsair Techinvest Ltd One Advice Group plc

Fineguard Ltd Ultimate Finance Group plc

Augean plc

Disperse Ltd

Dovehoco 201 Ltd

Avingtrans plc

IS Solutions plc

Swallowfield plc

Alkane Energy plc

Renovo plc

Servelec Group plc

 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies. 

 

At the AGM, held on 30 June 2014, it was announced that Steve Harris, the Chairman, was proposing to retire and he has now formally stepped down as a director.

 

The Board of Proteome Sciences would like to thank him for the considerable contribution and support that he has provided to the Company over the last 20 years, a period in which the Company's outstanding biomarker research has been converted into products, services and commercial revenue. We wish him a long and enjoyable retirement.

 

The CEO, Christopher Pearce, has been appointed Executive Chairman. Dr. Ian Pike remains the Chief Operating Officer.

 

 

- Ends -

 

 

 

 

 

 

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Tel: +44 (0)1932 865065

Dr. Ian Pike, Chief Operating Officer

James Malthouse, Finance Director

Nominated Adviser

Cenkos

Stephen Keys/Callum Davidson

Tel: +44 (0)20 7397 8900

Public Relations

IKON Associates

Adrian Shaw

Tel: +44 (0)1483 271291

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKBLFXZQFEBBD
Date   Source Headline
10th Oct 20073:31 pmPRNNotifiable Interest
8th Oct 20072:34 pmPRNStatement regarding mailing of interim report
2nd Oct 20074:28 pmPRNDirectorate Change
28th Sep 20078:00 amPRNInterim Results
21st Sep 20079:54 amPRNPress Release re Intronn Inc.
6th Sep 20074:27 pmPRNNotifiable Interest
17th Aug 20076:15 pmPRNAIM Rule 26 & Adviser Name
30th Jul 20077:00 amPRNStatement re US Patent Allowed
25th Jul 200712:03 pmPRNDirector's Dealing
12th Jul 20072:58 pmPRNNotifiable Interest
2nd Jul 20074:59 pmPRNDirector/PDMR Shareholding
29th Jun 20078:15 amPRNFurther Loan Agreement
29th Jun 20078:00 amPRNFinal Results
22nd May 20073:50 pmPRNNotifiable Interest
15th May 200711:38 amPRNGrant of European Patent
14th May 200711:40 amPRNNotifiable Interest
10th May 20075:03 pmPRNNotifiable Interest
8th May 20078:30 amPRNNotice of Allowance of TMT1 Patent in Canada
25th Apr 20073:32 pmPRNBlocklisting - Interim Review
20th Apr 200711:03 amPRNDirector's Dealings
19th Apr 20072:26 pmPRNNotifiable Interest
18th Apr 20078:30 amPRNService Agreement with Onconome Inc.
13th Apr 200712:20 pmPRNNotifiable Interest
13th Apr 200712:13 pmPRNNotifiable Interest
21st Mar 20077:00 amPRNHolding(s) in Company
21st Mar 20077:00 amPRNHolding(s) in Company
21st Mar 20077:00 amPRNHolding(s) in Company
21st Feb 20079:41 amPRNPress Release
19th Feb 20074:40 pmPRNHolding(s) in Company
15th Jan 20077:00 amPRNStatement re Issuance of Patent
5th Jan 200712:29 pmPRNHolding(s) in Company
21st Dec 20064:59 pmPRNHolding(s) in Company
18th Dec 20062:12 pmPRNStatement re: Patent
13th Dec 20062:07 pmPRNStatement re Issuance of Patent
13th Dec 200611:32 amPRNTotal Voting Rights
11th Dec 200610:49 amPRNStatement re: Issuance of Patent
31st Oct 200612:42 pmPRNHolding(s) in Company
30th Oct 20065:38 pmPRNBlocklisting
5th Sep 20069:54 amPRNDirectorate Change
27th Jul 20061:53 pmPRNHolding(s) in Company
27th Jul 200612:04 pmPRNResult of AGM
18th Jul 20067:00 amPRNAppointment
17th Jul 20064:41 pmRNSSecond Price Monitoring Extn
17th Jul 20064:36 pmRNSPrice Monitoring Extension
6th Jul 20065:12 pmPRNHolding(s) in Company
4th Jul 20064:42 pmRNSSecond Price Monitoring Extn
4th Jul 20064:36 pmRNSPrice Monitoring Extension
29th Jun 20062:00 pmPRNFinal Results
28th Jun 20064:42 pmRNSSecond Price Monitoring Extn
28th Jun 20064:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.